Two days after Intellia voluntarily paused dosing due to safety concerns, the regulator stepped in with an official hold that ...

Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...

After Intellia Therapeutics paused a pair of phase 3 trials for its CRISPR therapy in response to a liver safety signal, the ...

Intellia paused both trials after receiving a report of grade 4 liver enzymes and increased total bilirubin in a patient in ...

A poorly characterized protein, historically thought to be a chaperon or enzyme, may actually be a key player in prostate ...

A study volunteer receiving Intellia’s transthyretin amyloidosis treatment was hospitalized due to severe signs of liver ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...

Intellia earlier this year reported a similar grade 4 liver enzyme elevation associated with the gene therapy nexiguran ...

Caribou Biosciences shares rose after its CAR-T therapies showed high response rates and durable remissions in lymphoma and myeloma trials.

Intellia Therapeutics has paused dosing in its Phase 3 MAGNITUDE trials after a patient experienced severe liver toxicity, as ...

In a first for adults in Singapore, scientists are conducting gene editing trials on heart patients to correct defects at ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...